J J Costanzi

1.5k total citations
36 papers, 1.2k citations indexed

About

J J Costanzi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, J J Costanzi has authored 36 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Genetics. Recurrent topics in J J Costanzi's work include Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). J J Costanzi is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Breast Cancer Treatment Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). J J Costanzi collaborates with scholars based in United States, Egypt and Germany. J J Costanzi's co-authors include Saul E. Rivkin, Barth Hoogstraten, John D. Bonnet, Anatolio B. Cruz, Charles A. Coltman, Tate Thigpen, Richard B. Pollard, Howard Ozer, William R. Jewell and Noboru Oishi and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of the New York Academy of Sciences.

In The Last Decade

J J Costanzi

36 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J J Costanzi United States 20 641 295 283 272 187 36 1.2k
Hwee‐Yong Yap United States 18 765 1.2× 204 0.7× 398 1.4× 174 0.6× 98 0.5× 31 1.3k
Reginald P. Pugh United States 19 581 0.9× 217 0.7× 269 1.0× 221 0.8× 171 0.9× 34 1.1k
M Weil France 16 446 0.7× 285 1.0× 174 0.6× 108 0.4× 374 2.0× 69 1.1k
Verena Hug United States 16 767 1.2× 234 0.8× 186 0.7× 688 2.5× 132 0.7× 44 1.4k
John D. Bonnet United States 22 1.0k 1.6× 620 2.1× 264 0.9× 127 0.5× 745 4.0× 41 1.7k
A Mangalik United States 10 917 1.4× 203 0.7× 368 1.3× 422 1.6× 162 0.9× 32 1.4k
Ellen R. Gaynor United States 22 751 1.2× 199 0.7× 292 1.0× 324 1.2× 105 0.6× 42 1.6k
P Hurteloup France 15 975 1.5× 297 1.0× 429 1.5× 410 1.5× 439 2.3× 32 2.0k
Alan Barge United Kingdom 14 819 1.3× 411 1.4× 250 0.9× 166 0.6× 664 3.6× 21 1.5k
F J Cummings United States 20 691 1.1× 116 0.4× 159 0.6× 300 1.1× 51 0.3× 35 1.2k

Countries citing papers authored by J J Costanzi

Since Specialization
Citations

This map shows the geographic impact of J J Costanzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J J Costanzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J J Costanzi more than expected).

Fields of papers citing papers by J J Costanzi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J J Costanzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J J Costanzi. The network helps show where J J Costanzi may publish in the future.

Co-authorship network of co-authors of J J Costanzi

This figure shows the co-authorship network connecting the top 25 collaborators of J J Costanzi. A scholar is included among the top collaborators of J J Costanzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J J Costanzi. J J Costanzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rivkin, Saul E., Joe M. O’Sullivan, Anatolio B. Cruz, et al.. (1996). Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.. Journal of Clinical Oncology. 14(1). 46–51. 65 indexed citations
3.
Rivkin, Saul E., Barbara Metch, Anatolio B. Cruz, et al.. (1994). Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.. Journal of Clinical Oncology. 12(10). 2078–2085. 82 indexed citations
4.
Rivkin, Saul E., Barbara Metch, William R. Jewell, et al.. (1993). One versus 2 years of CMFVP adjuvant chemotherapy in axillary node-positive and estrogen receptor-negative patients: a Southwest Oncology Group study.. Journal of Clinical Oncology. 11(9). 1710–1716. 16 indexed citations
5.
Panettiere, Frank J., Phyllis J. Goodman, J J Costanzi, et al.. (1988). Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.. Journal of Clinical Oncology. 6(6). 947–954. 61 indexed citations
6.
Eyre, Harmon J., James R. Eltringham, E. A. Gehan, et al.. (1986). Randomized comparisons of radiotherapy and carmustine versus procarbazine versus dacarbazine for the treatment of malignant gliomas following surgery: a Southwest Oncology Group Study.. PubMed. 70(9). 1085–90. 15 indexed citations
7.
Oishi, Noboru, Sewa S. Legha, Joseph D. McCracken, et al.. (1984). Phase II trial of amsacrine in pancreatic carcinoma: a Southwest Oncology Group study.. PubMed. 68(11). 1411–2. 2 indexed citations
8.
Gagliano, Robert G., Richard Stephens, J J Costanzi, et al.. (1984). Randomized trial of hexamethylmelamine versus 5-FU, doxorubicin, and cyclophosphamide (FAC) in advanced transitional cell bladder carcinoma: a Southwest Oncology Group study.. PubMed. 68(7-8). 1025–6. 9 indexed citations
9.
Panettiere, Frank J., Charles D. Haas, Brian R. McDonald, et al.. (1984). Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.. Journal of Clinical Oncology. 2(5). 420–424. 27 indexed citations
10.
Stewart, DavidJ., et al.. (1983). Phase II study of cisplatin in recurrent astrocytomas in adults: A southwest oncology group study. Journal of Neuro-Oncology. 1(2). 145–7. 57 indexed citations
11.
Barranco, S. C., et al.. (1982). Use of 1,2:5,6-dianhydrogalactitol in studies on cell kinetics-directed chemotherapy schedules in human tumors in vivo.. PubMed. 42(7). 2899–2905. 11 indexed citations
12.
Tranum, Bill L., Brenna C. McDonald, Tate Thigpen, et al.. (1982). Adriamycin combinations in advanced breast cancer:A southwest oncology group study. Cancer. 49(5). 835–839. 37 indexed citations
13.
Knight, W. Andy, et al.. (1979). Methyl glyoxal bis guanylhydrazone (methyl GAG, MCBG) in advanced human malignancy. Proceedings of the American Association for Cancer Research. 20. 6 indexed citations
14.
Mahan, James M., Billy U. Philips, & J J Costanzi. (1978). Patient referrals. Academic Medicine. 53(3). 210–1. 7 indexed citations
15.
Tranum, Bill L., Barth Hoogstraten, Alexander Kennedy, et al.. (1978). Adriamycin in combination for the treatment of breast cancer.A southwest oncology group study. Cancer. 41(6). 2078–2083. 40 indexed citations
16.
Costanzi, J J. (1976). DTIC (NSC-45388) studies in the southwest oncology group.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 60(2). 189–92. 27 indexed citations
17.
Mahan, James M., et al.. (1976). The tracer method of curriculum analysis in cancer education. Academic Medicine. 51(6). 512–4. 2 indexed citations
18.
Jenkins, V. K., J J Costanzi, & Howard Ellis. (1976). Effects of single and combined chemotherapeutic agents on hemopoietic stem cells in mice. American Journal of Hematology. 1(1). 79–88. 10 indexed citations
19.
Hoogstraten, Barth, Stephen L. George, Saul E. Rivkin, et al.. (1976). Combination chemotherapy and adriamycin in patients with advanced breast cancer.A Southwest Oncology Group study. Cancer. 38(1). 13–20. 127 indexed citations
20.
Sakai, Hideto, et al.. (1975). Thymosin-induced increase in E-rosette-forming capacity of lymphocytes in patients with malignant neoplasms. Cancer. 36(3). 974–976. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hwee‐Yong Yap Breakdown of academic impact, for papers by Reginald P. Pugh Breakdown of academic impact, for papers by M Weil Breakdown of academic impact, for papers by Verena Hug Breakdown of academic impact, for papers by John D. Bonnet Breakdown of academic impact, for papers by A Mangalik Breakdown of academic impact, for papers by Ellen R. Gaynor Breakdown of academic impact, for papers by P Hurteloup Breakdown of academic impact, for papers by Alan Barge Breakdown of academic impact, for papers by F J Cummings
Rankless by CCL
2026